SCHEMBL723476

SCHEMBL723476

O=C(CCl)Nc1ccc(Oc2ccnc3cc(-c4ccccc4)oc23)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNF4 P78317 1/20 0.52
ALDH1A1 P00352 3/20 0.47
HTT P42858 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
GLA P06280 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
MITF O75030 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
PDGFRA P16234 3/20 0.45
KDR P35968 2/20 0.45
POLB P06746 1/20 0.44
MAPK1 P28482 1/20 0.44
BRAF P15056 1/20 0.43
MET P08581 6/20 0.43
KIT P10721 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723189 0.91 ALDH1A1 (0.54) RNF4ALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL722298 0.90 MITF (0.56) RNF4ALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL723784 0.90 ALDH1A1 (0.53) RNF4ALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL724014 0.90 NPC1 (0.47) ALDH1A1MAPTNPC1RAB9APDGFRA
SCHEMBL721787 0.84 TGM2 (0.52) PDGFRAKDRKITAXLMAP2K7
SCHEMBL723733 0.83 ALDH1A1 (0.46) RNF4ALDH1A1HTTSMN1; SMN2MAPT
SCHEMBL723499 0.81 HTT (0.43) RNF4ALDH1A1HTTSMN1; SMN2MITF
SCHEMBL723378 0.81 CYP3A4 (0.47) ALDH1A1HTTSMN1; SMN2MAPTLMNA
SCHEMBL723786 0.80 CYP3A4 (0.48) ALDH1A1SMN1; SMN2MAPTLMNACYP1A2
SCHEMBL723570 0.80 CYP3A4 (0.46) ALDH1A1HTTSMN1; SMN2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB RNF4 1004/4885ALDH1A1 1457/4885HTT 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.